Developing a Biological Safety Evaluation
Date: April 18, 2017 (60 minutes)
- Audrey Turley, B.S., RM (NCRM), CBA (ASQ), Research Scientist, Nelson Labs
The three main steps in developing a Biological Safety Evaluation (BSE) are:
A BEP is developed based on the risk of the device to the patient. With this in mind, several factors need to be considered to ensure that unnecessary testing is avoided. A useful testing plan will address the device as a whole, starting with materials and processes and ending with patient exposure (type and duration).
- 1) Biological Evaluation Plan (BEP)
- 2) Perform Testing and Written Risk Assessments
- 3) Biological Evaluation Report (BER)
An understanding of testing options is crucial as the approach to determining the safety of a device is moving away from check box based decisions to scientific justification for when testing is necessary and when it is not. This will include a discussion about changes in the regulatory world that include an important use for chemistry testing.
As biological safety evaluations become more complex, a summary report is essential to draw the right conclusions from the data submitted to support the overall safety of a medical device. A written assessment is requested in ISO 10993-1 as well as in the FDA guidance document. The webinar will go over the information needed and the important points that should be included in the report.
This webinar will also include discussion of how to assess the biocompatibility of device and process changes. Composed of a 50-minute presentation followed by a Q&A session, the webinar will cover the broad scope of developing a biological safety evaluation. This webinar will be based on ISO 10993-1 and the FDA Guidance document on ISO 10093-1 (effective September 2016).
Keywords: Biological Safety Evaluation, Medical Device, Biocompatibility, FDA, ISO 10993
Audrey Turley, B.S., RM (NCRM), CBA (ASQ), Research Scientist, Nelson Labs
Audrey Turley has 20 years of experience working in research, laboratory, and test design functions in the medical device industry. She is a biocompatibility expert having performed all the in vitro tests offered at Nelson Laboratories, which include cytotoxicity (MEM and agar overlay), hemolysis (PTT, PT, complement activation, blood circulation, ASTM and NIH methods), and genotoxicity (Ames and chromosome aberration).
Audrey is an active committee member of many working groups with the Association for the Advancement of Medical Instrumentation (AAMI):
- BE/WG 06 – Mutagen, carcinogen, reproduction toxicity
- BE/WG 07 – Systemic toxicity>
- BE/WG 08 – Irritation and sensitization
- BE/WG 10 – Implantation
- BE/WG 11 – Allowable limits for leachable substances
|THIS PROGRAM IS INTENDED FOR|
- Medical Device Consultants
- Medical Device Engineers
- Quality Assurance/Quality Control (medical device industry)
- Regulatory/Compliance (medical device industry)
- R&D (medical device industry)
|OUR XTALKS PARTNER FOR THIS EVENT|
Established in 1985, Nelson Laboratories is a leading provider of microbiological testing and consulting services for MedTech companies. We know that every test matters and requires solutions that improve patient outcomes and minimize customer risk. We call it “The Science of Success®.” It means working with customers to solve complex problems, providing precise test results, and delivering value through superior testing solutions and service to ensure the safety and efficacy of every product. Nelson Laboratories is a standalone business within Sterigenics International LLC, the global leader in outsourced contract sterilization services, gamma technologies, and medical isotopes. Visit www.nelsonlabs.com
for more information.